Farmacom spends 1m euros to catch up

Brasov-based Farmacom expects to post more than 13.7 million euro turnover for this year, up some 20% on 2004. To attain this figure, the company”s management relies on the distribution and sale of drugs through its own drugstores, given that production was halted last year in view of upgrades. “The projected growth is due to the constant development of the market and to the consumption of generic drugs being higher and higher by the year,” Romeo Fieraru, Farmacom”s general manager told ZF Transilvania. As the production space was not in line with the European legislation in this field the company began carrying out an investment programme worth more than one million euros in order to comply. “The investments in rearranging the production space began in 2004 in order to attain the GMP (Good Manufacturing Practice) certification, i.e. have the locations we use for production match the type of drugs we make, that is anodynes and antibiotics,” Fieraru said. ZF